Takeaways from Tuesday's Annual Meeting: With just a single dose, 100%-owned M281 MaB suppresses bad circulating levels of IgG antibodies for up to a month far better than any currently available drug does, and could potentially reach a huge market. Per the pipeline, http://www.momentapharma.com/pipeline/pipeline.php, Phase 1 results are expected in 2H 2017.
CW is extremely pleased with the fact that due to the fortuitous event of Baxalta's being acquired by Shire, MNTA owns the M923 Humira biosimilar 100%. He did, however, mention the difficulty of overcoming the protection afforded by ABBV's more than 100 patents around the drug.
I did relay this group's concerns about the possibility of further dilution, and CW introduced me to Scott Storer the new CFO, who said he doesn't see any need to hit the capital markets again in the near future (with $400MM in the bank and further milestone payments due this year, why would they?).
They treated me like a king, as I was the only stockholder that bothered to attend. BTW, I highly recommend the Kimpton Hotel's valet parking--for anyone considering attending next year.
News 
Market Data 
Discover 
